The treatment of systemic sclerosis (SSc) is complex as multiple organs are frequently involved and treatment is either for overall disease modification or is organ specific. EULAR has updated its treatment recommendations for SSc, reflecting data from some new trials. However, some features of SSc are not included.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The frequency of Raynaud’s phenomenon, very early diagnosis of systemic sclerosis, and systemic sclerosis in a large Veteran Health Administration database
BMC Rheumatology Open Access 15 October 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Muangchan, C., Canadian Scleroderma Research Group, Baron, M. & Pope, J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J. Rheumatol. 40, 1545–1556 (2013).
Pope, J. E., Ouimet, J. M. & Krizova, A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Care Res. 55, 138–145 (2006).
Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209909 (2016).
Khanna, D. et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 315, 1975–1988 (2016).
Abou-Raya, A., Abou-Raya, S. & Helmii, M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J. Rheumatol. 35, 1801–1808 (2008).
Denton, C. P. et al. Long-term effects of Bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 67, 1222–1228 (2008).
Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006).
Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630–2640 (2016).
Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708–719 (2016).
Denton, C. P. et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 55, 1906–1919 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.E.P. acts as a consultant for Actelion, Bayer, Biogen, BMS, Merck, Roche, Pfizer. She has received funding for clinical trials from Actelion, Bayer, BMS, Roche.
Supplementary information
Supplementary information S1 (table)
Comments on the updated EULAR systemic sclerosis treatment recommendations (PDF 134 kb)
Rights and permissions
About this article
Cite this article
Pope, J. Reflections on the EULAR recommendations for the treatment of systemic sclerosis. Nat Rev Rheumatol 13, 134–136 (2017). https://doi.org/10.1038/nrrheum.2016.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.212
